Total Payments
$112,066
2024 Payments
$314.34
Companies
15
Transactions
103
Medicare Patients
1,114
Medicare Billing
$138,399
Payment Breakdown by Category
Consulting$61,162 (54.6%)
Research$33,194 (29.6%)
Other$10,095 (9.0%)
Travel$4,983 (4.4%)
Food & Beverage$2,532 (2.3%)
Education$100.18 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,162 | 19 | 54.6% |
| Unspecified | $33,194 | 23 | 29.6% |
| Travel and Lodging | $4,983 | 15 | 4.4% |
| Current or prospective ownership or investment interest | $4,395 | 3 | 3.9% |
| Honoraria | $3,150 | 1 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,550 | 1 | 2.3% |
| Food and Beverage | $2,532 | 35 | 2.3% |
| Education | $100.18 | 6 | 0.1% |
Payments by Type
General
$78,872
80 transactions
Research
$33,194
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85,174 | 51 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $8,003 | 8 | $0 (2019) |
| Esaote North America, Inc. | $4,395 | 3 | $0 (2019) |
| WHITEHALL INTERNATIONAL INC | $3,400 | 1 | $0 (2020) |
| Horizon Therapeutics plc | $3,258 | 4 | $0 (2019) |
| Gilead Sciences, Inc. | $2,637 | 14 | $0 (2020) |
| PFIZER INC. | $2,587 | 5 | $0 (2021) |
| Alexion Pharmaceuticals, Inc. | $1,600 | 1 | $0 (2021) |
| ABBVIE INC. | $281.95 | 5 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $212.81 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $314.34 | 5 | GENZYME CORPORATION ($92.14) |
| 2023 | $359.73 | 4 | GENZYME CORPORATION ($118.11) |
| 2022 | $7,962 | 4 | Novartis Pharmaceuticals Corporation ($7,878) |
| 2021 | $16,350 | 7 | Novartis Pharmaceuticals Corporation ($12,180) |
| 2020 | $11,696 | 19 | Novartis Pharmaceuticals Corporation ($6,631) |
| 2019 | $38,247 | 32 | Novartis Pharmaceuticals Corporation ($21,639) |
| 2018 | $2,237 | 10 | Novartis Pharmaceuticals Corporation ($1,972) |
| 2017 | $34,900 | 22 | Novartis Pharmaceuticals Corporation ($34,715) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/17/2024 | ABBVIE INC. | SKYRIZI (Drug), RINVOQ, SKYRIZI | Food and Beverage | In-kind items and services | $40.40 | General |
| Category: IMMUNOLOGY | ||||||
| 11/03/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $70.43 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/01/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $92.14 | General |
| Category: Rheumatology | ||||||
| 06/20/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $88.49 | General |
| Category: Dermatology | ||||||
| 03/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $61.52 | General |
| Category: IMMUNOLOGY | ||||||
| 09/28/2023 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $118.11 | General |
| Category: Rheumatology | ||||||
| 06/15/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $71.02 | General |
| Category: Dermatology | ||||||
| 06/01/2023 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $109.08 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/21/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | COSENTYX (Biological) | — | In-kind items and services | $2,415.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: IMMUNOLOGY | ||||||
| 11/14/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/14/2022 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $5,462.50 | General |
| Category: IMMUNOLOGY | ||||||
| 07/29/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $64.18 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 10/01/2021 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Education | In-kind items and services | $19.69 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 08/13/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | — | In-kind items and services | $2,400.00 | Research |
| Study: A PHASE III RANDOMIZED DOUBLE BLINDED PLACEBO CONTROLLED MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB 150MG AND 300MG IN PREFILLED SYRINGE TO EMONSTRATE EFFICACY INCLUDING INHIBITION OF STRUCTURAL DAMAGE SAFETY AND TOLERABILITY UP TO 2 YEARS IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS FUTURE 5 • Category: IMMUNOLOGY | ||||||
| 07/21/2021 | Alexion Pharmaceuticals, Inc. | Strensiq (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Endocrinology | ||||||
| 04/27/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $5,050.00 | General |
| 01/28/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | — | In-kind items and services | $2,205.00 | Research |
| Study: A RANDOMIZED DOUBLE BLIND ACTIVE CONTROL MULTICENTER STUDY TO EVALUATE THE EFFICACY AT WEEK 52 OF SUBCUTANEOUSLY ADMINISTERED SECUKINUMAB MONOTHERAPY COMPARED WITH SUBCUTANEOUSLY ADMINISTERED ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS • Category: IMMUNOLOGY | ||||||
| 01/27/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $2,525.00 | General |
| Category: DERMATOLOGY | ||||||
| 01/18/2021 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| 12/11/2020 | WHITEHALL INTERNATIONAL INC | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/05/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | — | In-kind items and services | $675.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: DERMATOLOGY | ||||||
| 10/29/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | — | In-kind items and services | $614.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: DERMATOLOGY | ||||||
| 10/15/2020 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Education | In-kind items and services | $43.75 | General |
| Category: IMMUNOLOGY | ||||||
| 06/16/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $14,012 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,622 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,415 | 1 |
| A PHASE III RANDOMIZED DOUBLE BLINDED PLACEBO CONTROLLED MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB 150MG AND 300MG IN PREFILLED SYRINGE TO EMONSTRATE EFFICACY INCLUDING INHIBITION OF STRUCTURAL DAMAGE SAFETY AND TOLERABILITY UP TO 2 YEARS IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS FUTURE 5 | Novartis Pharmaceuticals Corporation | $2,400 | 1 |
| A RANDOMIZED DOUBLE BLIND ACTIVE CONTROL MULTICENTER STUDY TO EVALUATE THE EFFICACY AT WEEK 52 OF SUBCUTANEOUSLY ADMINISTERED SECUKINUMAB MONOTHERAPY COMPARED WITH SUBCUTANEOUSLY ADMINISTERED ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS | Novartis Pharmaceuticals Corporation | $2,205 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,833 | 4 |
| A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. | Gilead Sciences, Inc. | $1,622 | 10 |
| A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis | Gilead Sciences, Inc. | $84.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 254 | 462 | $113,118 | $33,379 |
| 2022 | 10 | 292 | 481 | $117,184 | $36,739 |
| 2021 | 8 | 286 | 512 | $125,801 | $38,699 |
| 2020 | 8 | 282 | 452 | $102,880 | $29,581 |
Total Patients
1,114
Total Services
1,907
Medicare Billing
$138,399
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 239 | $60,706 | $22,362 | 36.8% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 51 | 73 | $25,915 | $3,101 | 12.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 22 | 40 | $10,160 | $3,062 | 30.1% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 11 | 21 | $6,132 | $1,692 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $3,784 | $1,574 | 41.6% |
| 76882 | Limited ultrasound scan of joint or other extremity structure except blood vessels | Office | 2023 | 20 | 28 | $4,788 | $907.98 | 19.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 13 | 13 | $741.00 | $393.12 | 53.1% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 11 | 19 | $532.00 | $178.78 | 33.6% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 11 | 18 | $360.00 | $107.99 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 103 | 249 | $63,246 | $23,547 | 37.2% |
| 76881 | Complete ultrasound scan of joint | Office | 2022 | 51 | 64 | $22,720 | $2,937 | 12.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 16 | $5,504 | $1,890 | 34.3% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2022 | 16 | 23 | $6,716 | $1,795 | 26.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $5,516 | $1,737 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 19 | $3,192 | $1,173 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 16 | $4,064 | $1,087 | 26.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 14 | 14 | $1,414 | $959.56 | 67.9% |
| 76882 | Limited ultrasound scan of joint or other extremity structure lacking blood vessels | Office | 2022 | 13 | 17 | $2,907 | $767.10 | 26.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 24 | 25 | $1,425 | $717.68 | 50.4% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 14 | 24 | $480.00 | $129.39 | 27.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 237 | $60,198 | $23,224 | 38.6% |
| 76881 | Complete ultrasound of arm or leg | Office | 2021 | 59 | 81 | $28,755 | $4,195 | 14.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 52 | $8,736 | $3,161 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 31 | $7,874 | $2,537 | 32.2% |
| 76882 | Partial ultrasound of joint or other non-blood vessel structure of arm or leg | Office | 2021 | 32 | 45 | $7,695 | $1,941 | 25.2% |
About Dr. Gurjit Kaeley, MD
Dr. Gurjit Kaeley, MD is a Rheumatology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457319741.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gurjit Kaeley, MD has received a total of $112,066 in payments from pharmaceutical and medical device companies, with $314.34 received in 2024. These payments were reported across 103 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($61,162).
As a Medicare-enrolled provider, Kaeley has provided services to 1,114 Medicare beneficiaries, totaling 1,907 services with total Medicare billing of $138,399. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Jacksonville, FL
- Active Since 05/03/2006
- Last Updated 11/06/2009
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1457319741
Products in Payments
- COSENTYX (Biological) $79,679
- Tremfya (Drug) $8,003
- XELJANZ (Drug) $3,437
- KRYSTEXXA (Biological) $3,258
- SL3116 Linear Probe (Device) $1,764
- BL433 Linear Probe (Device) $1,646
- Strensiq (Drug) $1,600
- CA541 Convex Probe (Device) $984.90
- LUPKYNIS (Drug) $212.81
- KEVZARA (Biological) $210.25
- COSENTYX (Drug) $159.51
- REMICADE (Biological) $125.00
- RINVOQ (Biological) $84.40
- SAPHNELO (Biological) $70.43
- Prolia (Biological) $59.89
- BENLYSTA (Biological) $43.75
- SKYRIZI (Drug) $40.40
- Humira (Biological) $32.16
- SIMPONI ARIA (Biological) $8.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Jacksonville
Dr. Swati Shah, Mbbs, MBBS
Rheumatology — Payments: $73,280
Rheumatology $73,280
Dr. Steven Mathews, Md, MD
Rheumatology — Payments: $49,388
Rheumatology $49,388
Andy Abril, Md, MD
Rheumatology — Payments: $20,122
Rheumatology $20,122
Dr. Gary Gabor, Md, MD
Rheumatology — Payments: $16,986
Rheumatology $16,986
Ronald Butendieck, Md, MD
Rheumatology — Payments: $16,596
Rheumatology $16,596
Annabelle Lee, Md, MD
Rheumatology — Payments: $7,883
Rheumatology $7,883